Skip to main content

Advertisement

SpringerLink
Log in

Dyslipidemia in type 2 diabetes mellitus

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus (DM). DM is now recognized as a risk equivalent for coronary heart disease. The lipid profile in patients with type 2 DM is characterized by elevated triglycerides, low levels of high-density lipoprotein cholesterol, and small dense low-density lipoprotein cholesterol (LDLC) particles and is believed to be a key factor promoting atherosclerosis in these patients. Both primary and secondary prevention studies have provided ample evidence that aggressive statin therapy reduces cardiovascular end points in patients with DM. In all persons with DM, current treatment guidelines recommend reduction of LDLC to less than 100 mg/dL, regardless of baseline lipid levels. Lowering LDLC to less than 70 mg/dL may provide even greater benefits, particularly in very high risk patients with DM and coronary heart disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.

    Article  PubMed  CAS  Google Scholar 

  2. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998, 21:69–75.

    Article  PubMed  CAS  Google Scholar 

  3. Garg A, Grundy SM: Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153–169.

    Article  PubMed  CAS  Google Scholar 

  4. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893–2898.

    Article  PubMed  CAS  Google Scholar 

  5. Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004, 173:1–12.

    Article  PubMed  CAS  Google Scholar 

  6. Duvillard L, Pont F, Florentin E, et al.: Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000, 30:685–694.

    Article  PubMed  CAS  Google Scholar 

  7. Rashid S, Uffelman KD, Lewis GF: The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002, 16:24–28.

    Article  PubMed  Google Scholar 

  8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2589.

  9. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  10. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.

    Article  PubMed  Google Scholar 

  11. Colhoun HM, Betteridge DJ, Durrington PN: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  12. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.

    Article  PubMed  CAS  Google Scholar 

  13. Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614–620.

    Article  PubMed  CAS  Google Scholar 

  14. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513–2519.

    PubMed  CAS  Google Scholar 

  15. Keech A, Colquhoun D, Best J, et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713–2721.

    Article  PubMed  CAS  Google Scholar 

  16. Sacks FM, Tonkin AM, Craven T, et al.: Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105:1424–1428.

    Article  PubMed  CAS  Google Scholar 

  17. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  18. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  19. Shepherd J, Barter P, Carmena R, et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220–1226.

    Article  PubMed  CAS  Google Scholar 

  20. American Diabetes Association: Standards of medical care in diabetes—2006. Diabetes Care 2006, 29(suppl 1):S4–S42.

    Google Scholar 

  21. Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002, 105:2341–2346.

    Article  PubMed  CAS  Google Scholar 

  22. Gagne C, Bays HE, Weiss SR, et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084–1091.

    Article  PubMed  CAS  Google Scholar 

  23. Crouse JR 3rd: Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987, 83:243–248.

    Article  PubMed  Google Scholar 

  24. Yuan J, Tsai MY, Hunninghake DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994, 110:1–11.

    Article  PubMed  CAS  Google Scholar 

  25. Prueksaritanont T, Zhao JJ, Ma B: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301:1042–1051.

    Article  PubMed  CAS  Google Scholar 

  26. Miller M: Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 2003, 78:735–742.

    Article  PubMed  CAS  Google Scholar 

  27. Gray DR, Morgan T, Chretien SD, et al.: Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994, 121:252–258.

    PubMed  CAS  Google Scholar 

  28. Yu-Poth S, Zhao G, Etherton T, et al.: Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999, 69:632–646.

    PubMed  CAS  Google Scholar 

  29. Chandalia M, Garg A, Lutjohann D, et al.: Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000, 342:1392–1398.

    Article  PubMed  CAS  Google Scholar 

  30. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453–458.

    Article  PubMed  CAS  Google Scholar 

  31. Palumbo PJ: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998, 12:110–119.

    Article  PubMed  CAS  Google Scholar 

  32. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  33. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.

    Article  CAS  Google Scholar 

  34. Gelfand EV, Cannon CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006, 47:1919–1926.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, University of Pennsylvania Medical Center and the Philadelphia Veterans Affairs Medical Center, 3900 Woodland Avenue, Philadelphia, PA, 19104, USA

    Frederick F. Samaha MD

Authors
  1. Ramprasad Gadi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick F. Samaha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederick F. Samaha MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gadi, R., Samaha, F.F. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 7, 228–234 (2007). https://doi.org/10.1007/s11892-007-0036-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-007-0036-0

Keywords

Search

Navigation